This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Manrique, R.V. Articles by Manrique, V. Search for Related Content PubMed PubMed Citation Articles by Manrique, R.V. Articles by Manrique, V. Social Bookmarking                         What's this?

Platelet Resistance to Prostacyclin. Enhancement of the Antiaggregatory Effect of Prostacyclin by Pentoxifylline

Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil

V. Manrique, M.D.

Biochemical Department, Universidad de San Marcos, Lima, Peru

With regard to existence of high prostacyclin (PGI₂) levels during atheromatosis and thrombus formation, resistance of platelets to prostacyclin and its analogues seems to play an important pathophysiologic key role for the clarifying of vasoocclusive phenomena.

Platelet resistance to prostacyclin was studied in vitro and ex vivo in 160 atherosclerotic patients (assessed by objective diagnostic criteria) with and without thrombotic complications and in 50 controls. Prostacyclin resistance phenomena were more pronounced and frequent in patients with occlusive complications, the difference from controls being statistically significant. However, there was no significant difference between the controls and the nonthrombotic patient sample.

The intraplatelet cAMP levels might be the metabolic basis of the PGI₂ resistance phenomenon, because in the patient group, platelet cAMP levels were decreased by 50% after Ca²⁺ stimulation.

Compared to controls ß-thromboglobulin and thromboxane B₂ plasma levels were significantly increased (30±9 to 87±26 ng/ml and 9±5 to 54±21 pg/ml, respectively), confirming the hyperreactivity state of resistant platelets.

From the therapeutic point of view, patients with resistant platelets require PGI₂ doses that cause, however, increased side effects. We were able to demonstrate in vivo that IV pretreatment with pentoxifylline—a known stimulator of cAMP formation in platelets—followed by a simultaneous and continuous IV infusion of PGI₂ + pentoxifylline, permitted us to reduce significantly the mean PGI₂ doses needed for triggering an antiplatelet effect, without inducing side effects. In ex vivo studies, PGI₂ resistant platelets of atherosclerotic patients pretreated with pentoxifylline showed normalized stimulation response, and platelet cAMP levels increased from 7.8±2.7 to 15.2±1.9 pmol/10⁸ platelets.

Our data disclose a synergistic antiplatelet effect of PGI₂ and pentoxifylline, which increases the antithrombotic potential and sheds light on the beneficial effects of pentoxifylline in the treatment of occlusive vascular disease.

Angiology, Vol. 38, No. 2, 101-108 (1987)
DOI: 10.1177/000331978703800202


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?